Studies evaluating the role of maintenance therapy with thalidomide in newly diagnosed patients with multiple myeloma (MM).
| . | . | . | . | Maintenance vs No Maintenance . | |||
|---|---|---|---|---|---|---|---|
| Cooperative Group . | N . | Initial dose (mg) . | Duration of T-maintenance . | CR+ VGPR, % . | EFS or PFS, % . | OS, % . | Reference . |
| CR indicates complete response; VGPR, very good partial response; EFS, event-free survival; PFS, progression-free survival; OS, overall survival; PD, progression of disease; NA, not available. | |||||||
| IFM | 597 | 400 | Until PD | 67 vs 55 | 3-y EFS | 4-y OS | Attal et al. Blood. 2006;108:3289–3294 |
| 52 vs 36 | 87 vs 77 | ||||||
| Australian | 243 | 200 | 12 months | 63 vs 40 | 3-y PFS | 3-y OS | Spencer et al. J Clin Oncol. 2009;27:1788–1793 |
| 42 vs 23 | 86 vs 75 | ||||||
| Arkansas | 668 | 400 | Throughout study | 62 vs 43 | 5-y EFS | 5-y OS | Barlogie et al. Blood. 2008;112:3115–3121 |
| 56 vs 45 | 67 vs 65 | ||||||
| MRC (UK) | 820 | 100 | Until PD | NA | HR:1.9 | Similar OS | Morgan et al. Blood. 2008;112:656a |
| P =.007 | |||||||
| . | . | . | . | Maintenance vs No Maintenance . | |||
|---|---|---|---|---|---|---|---|
| Cooperative Group . | N . | Initial dose (mg) . | Duration of T-maintenance . | CR+ VGPR, % . | EFS or PFS, % . | OS, % . | Reference . |
| CR indicates complete response; VGPR, very good partial response; EFS, event-free survival; PFS, progression-free survival; OS, overall survival; PD, progression of disease; NA, not available. | |||||||
| IFM | 597 | 400 | Until PD | 67 vs 55 | 3-y EFS | 4-y OS | Attal et al. Blood. 2006;108:3289–3294 |
| 52 vs 36 | 87 vs 77 | ||||||
| Australian | 243 | 200 | 12 months | 63 vs 40 | 3-y PFS | 3-y OS | Spencer et al. J Clin Oncol. 2009;27:1788–1793 |
| 42 vs 23 | 86 vs 75 | ||||||
| Arkansas | 668 | 400 | Throughout study | 62 vs 43 | 5-y EFS | 5-y OS | Barlogie et al. Blood. 2008;112:3115–3121 |
| 56 vs 45 | 67 vs 65 | ||||||
| MRC (UK) | 820 | 100 | Until PD | NA | HR:1.9 | Similar OS | Morgan et al. Blood. 2008;112:656a |
| P =.007 | |||||||